WAVE Life Sciences to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- WAVE Life Sciences Ltd. (NASDAQ: WVE), a genetic medicines company focused on developing targeted therapies for patients impacted by rare diseases, today announced that Paul Bolno, M.D., MBA, President and Chief Executive Officer, will be presenting at the following upcoming investor conferences:

• Leerink Partners Global Healthcare Conference 2017Wednesday, February 15th at 1:30 P.M. ET – New York

• RBC Capital Markets 2017 Healthcare ConferenceThursday, February 23rd at 2:05 P.M. ET – New York

A live webcast of each presentation will also be available on the investor relations page of the WAVE Life Sciences corporate website at http://ir.wavelifesciences.com. After each webcast, a replay will remain archived on the corporate website for a limited time.

About WAVE Life Sciences

At WAVE Life Sciences, we are driven by an unwavering passion and commitment to deliver on our mission of confronting challenging diseases by developing transformational therapies and empowering patients. We are utilizing our innovative and proprietary synthetic chemistry drug development platform to design, develop and commercialize rationally redesigned nucleic acid therapeutics that precisely target the underlying cause of rare and other serious genetically defined diseases. Given the versatility of our chemistry platform, WAVE’s deep, diverse pipeline spans multiple modalities including antisense, exon-skipping, and single-stranded RNAi. For more information, please visit www.wavelifesciences.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170206005286/en/

Media and Investors:
WAVE Life Sciences
Jillian Connell, 617-949-2981
Investor Relations
[email protected]
or
Feinstein Kean Healthcare
Gregory Kelley, 404-836-2302
[email protected]

Source: WAVE Life Sciences Ltd.

You May Also Be Interested In

• Wave Life Sciences to Present at Cantor 2026 Global Healthcare Conference
• Arthur J. Gallagher & Co. to Host Regularly Scheduled Quarterly Investor Meeting with Management
• Compliance as Competitive Edge, Rethinking Regulation in Cross-Border Fintech